Carlsmed Raises $52.5 Million in Series C

by Kay Aloha Villamor in March 19th, 2024

Carlsmed, a Carlsbad, CA-based AI-enabled personalized surgery medtech company, raised $52.5 million in Series C funding.  


The round was co-led by B Capital and U.S. Venture Partners.   

B Capital is a multi-stage global investment firm with more than $6 billion in assets under management across multiple funds, the firm focuses on seed to late-stage venture growth investments, primarily in the enterprise, financial technology, and healthcare sectors. Founded in 2015, B Capital leverages an integrated team across nine locations in the US and Asia, as well as a strategic partnership with BCG.  

U.S. Venture Partners (USVP) is a Silicon Valley venture capital firm. USVP has invested in over 500 companies spanning four decades. USVP focuses on early-stage start-ups that transform cybersecurity, enterprise software, consumer and healthcare. USVP is based in Menlo Park, California.  

Carlsmed Use of Funds  

The company will use the funding to accelerate the commercialization of the aprevo® personalized spine surgery platform for lumbar fusion procedures. Additionally, funds will support the development of aprevo® for cervical fusions, with a targeted launch in 2025.  

About Carlsmed  

Carlsmed is a medtech company that provides an AI-enabled personalized surgery platform. Their flagship product, the aprevo® personalized spine surgery platform, is designed to advance the standard of care for spine surgery one patient at a time. The company utilizes advanced technology to tailor surgical procedures to individual patients, enhancing effectiveness and recovery. Carlsmed's mission is to improve outcomes and decrease the cost of healthcare for spine surgery. 

Carlsmed has received Breakthrough Device designation from the FDA for aprevo® lumbar and cervical patient-specific interbody fusion devices. The company's implantable devices and software platforms are FDA-cleared for lumbar spine fusion, including anterior, lateral, and transforaminal approaches. 

Funding Details      

Company: Carlsmed, Inc.   

Raised: $52.5M  

Round: Series C  

Funding Month: March 2024      

Lead Investors: B Capital, U.S. Venture Partners  

Additional Investors:   

Company Website:   

Software Category: Medical  





Your cart